<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>D-C-M011-1053</udiDi>
    <basicUdiDi>B-C-M011-1053</basicUdiDi>
    <tradeName>MPO (QR101)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-M011-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.940Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N001-0158</udiDi>
    <basicUdiDi>B-C-N001-0158</basicUdiDi>
    <tradeName>NUT (QR043)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N001-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.920Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N001-025N7</udiDi>
    <basicUdiDi>B-C-N001-025N7</basicUdiDi>
    <tradeName>NUT (QR043)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N001-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.898Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N001-055G</udiDi>
    <basicUdiDi>B-C-N001-055G</basicUdiDi>
    <tradeName>NUT (QR043)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N001-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.877Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N001-1059</udiDi>
    <basicUdiDi>B-C-N001-1059</basicUdiDi>
    <tradeName>NUT (QR043)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N001-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.853Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N002-015F</udiDi>
    <basicUdiDi>B-C-N002-015F</basicUdiDi>
    <tradeName>Napsin A (QR058)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N002-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.834Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N002-025NJ</udiDi>
    <basicUdiDi>B-C-N002-025NJ</basicUdiDi>
    <tradeName>Napsin A (QR058)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N002-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.811Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N002-055P</udiDi>
    <basicUdiDi>B-C-N002-055P</basicUdiDi>
    <tradeName>Napsin A (QR058)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N002-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.788Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N002-105G</udiDi>
    <basicUdiDi>B-C-N002-105G</basicUdiDi>
    <tradeName>Napsin A (QR058)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N002-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.768Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N004-015V</udiDi>
    <basicUdiDi>B-C-N004-015V</basicUdiDi>
    <tradeName>NKX2.2 (QR077)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N004-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.750Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N004-025P8</udiDi>
    <basicUdiDi>B-C-N004-025P8</basicUdiDi>
    <tradeName>NKX2.2 (QR077)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N004-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.730Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N004-0565</udiDi>
    <basicUdiDi>B-C-N004-0565</basicUdiDi>
    <tradeName>NKX2.2 (QR077)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N004-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.711Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N004-105W</udiDi>
    <basicUdiDi>B-C-N004-105W</basicUdiDi>
    <tradeName>NKX2.2 (QR077)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N004-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.692Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N005-0164</udiDi>
    <basicUdiDi>B-C-N005-0164</basicUdiDi>
    <tradeName>NSE (QR104)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N005-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.673Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N005-025PK</udiDi>
    <basicUdiDi>B-C-N005-025PK</basicUdiDi>
    <tradeName>NSE (QR105)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N005-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.653Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N005-056C</udiDi>
    <basicUdiDi>B-C-N005-056C</basicUdiDi>
    <tradeName>NSE (QR104)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N005-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.633Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-N005-1065</udiDi>
    <basicUdiDi>B-C-N005-1065</basicUdiDi>
    <tradeName>NSE (QR104)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-N005-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.606Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-O001-015R</udiDi>
    <basicUdiDi>B-C-O001-015R</basicUdiDi>
    <tradeName>Olig2 (QR071)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-O001-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.584Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-O001-025NS</udiDi>
    <basicUdiDi>B-C-O001-025NS</basicUdiDi>
    <tradeName>Olig2 (QR071)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-O001-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.567Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-O001-055Z</udiDi>
    <basicUdiDi>B-C-O001-055Z</basicUdiDi>
    <tradeName>Olig2 (QR071)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-O001-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.546Z</lastUpdated>
  </row>
</eudamedExport>